NVO vs. REGN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or REGN.
Correlation
The correlation between NVO and REGN is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. REGN - Performance Comparison
Key characteristics
NVO:
0.15
REGN:
-0.73
NVO:
0.44
REGN:
-0.86
NVO:
1.05
REGN:
0.89
NVO:
0.14
REGN:
-0.40
NVO:
0.35
REGN:
-1.10
NVO:
12.98%
REGN:
14.62%
NVO:
30.53%
REGN:
21.90%
NVO:
-71.30%
REGN:
-91.81%
NVO:
-29.32%
REGN:
-40.54%
Fundamentals
NVO:
$486.49B
REGN:
$81.32B
NVO:
$2.99
REGN:
$40.40
NVO:
36.12
REGN:
18.32
NVO:
1.61
REGN:
1.10
NVO:
$270.58B
REGN:
$13.85B
NVO:
$229.07B
REGN:
$11.69B
NVO:
$135.97B
REGN:
$4.83B
Returns By Period
In the year-to-date period, NVO achieves a 1.09% return, which is significantly higher than REGN's -18.64% return. Over the past 10 years, NVO has outperformed REGN with an annualized return of 19.11%, while REGN has yielded a comparatively lower 5.28% annualized return.
NVO
1.09%
0.79%
-26.36%
3.23%
31.11%
19.11%
REGN
-18.64%
-6.22%
-31.23%
-15.77%
13.77%
5.28%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. REGN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. REGN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 1.40%, while REGN has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 1.40% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% | 1.72% |
REGN Regeneron Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
NVO vs. REGN - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.30%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for NVO and REGN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. REGN - Volatility Comparison
Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN) have volatilities of 7.70% and 7.55%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities